STAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026

Key Terms

phakic iols medical

Phakic intraocular lenses (phakic IOLs) are tiny corrective lenses surgically implanted inside the eye while leaving the eye’s natural lens intact; think of them as a permanent contact lens placed behind or in front of the pupil to correct high degrees of nearsightedness or astigmatism. Investors watch them because their adoption depends on regulatory approval, surgeon training, pricing and insurance coverage, and long‑term safety data — all factors that drive device sales, recurring clinical services and potential liability risk.

implantable collamer lenses medical

An implantable collamer lens is a small, soft lens surgically placed inside the eye to correct vision, acting much like a permanent contact lens implanted behind the iris instead of sitting on the eye surface. Investors care because these devices represent a durable, higher‑value medical product whose sales growth, regulatory approvals, safety record and reimbursement policies can directly affect a company’s revenue and risk profile, similar to how a popular new gadget can drive a maker’s earnings and reputation.

evo icl medical

A EVO ICL is a small, surgically implanted lens placed inside the eye to correct vision, functioning like a permanent contact lens positioned behind the iris. It matters to investors because its adoption, safety record, and regulatory approvals drive sales and future revenue for companies that make them; high demand or wider approvals can signal growth, while safety or competition can affect market share and profits.

intraocular lenses medical

Intraocular lenses are small, implantable lenses placed inside the eye to replace the eye’s natural lens, commonly used during cataract surgery or vision-correcting procedures. Think of them like swapping the lens in a camera to restore clarity; investors watch them because demand, pricing, regulatory approval and technological upgrades directly affect sales, clinical adoption and profit potential for medical device and eye‑care companies.

forward-looking statements regulatory

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

form 10-k regulatory

A Form 10-K is a comprehensive report that publicly traded companies are required to file annually with regulators. It provides a detailed overview of a company's financial health, operations, and risks, similar to a detailed health report. Investors use this information to assess the company's performance and make informed decisions about buying or selling its stock.

regulation fd regulatory

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

risk factors regulatory

Risk factors are elements or conditions that could cause an investment's value to decrease or lead to potential losses. They are like warning signs or obstacles that can affect the success of an investment, making it uncertain or more unpredictable. Recognizing risk factors helps investors understand the possible challenges and make more informed decisions.

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended January 2, 2026, on Tuesday, March 3 after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial results and business progress.

Event: STAAR Surgical Fourth Quarter and Fiscal Year 2025 Financial Results Webcast

Date: Tuesday, March 3, 2026

Time: 5:30 p.m. ET/ 2:30 p.m. PT

Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=J3bNAuVd

Topics on the call will include:

• Review of Fiscal Year 2025 Operations and Financial Results
• China Recovery and Operational Improvements
• Inventory Normalization
• Cost Discipline
• Update on Manufacturing Expansion in Switzerland
• Innovation Pipeline Progress
• 2026 Strategic Focus

The live webcast, including an option to pre-register, can be accessed at the preceding link or the “Investors” section of the STAAR website at https://investors.staar.com/. A webcast replay will be available at the same link for at least 90 days.

About STAAR Surgical

STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL’s are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye’s natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 3.5 million ICLs in over 75 countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit www.EVOICL.com. To learn more about STAAR, visit www.staar.com.

Safe Harbor

All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2026 and beyond or prospects for achieving such plans, expectations for sales, revenue, margin, expenses or earnings, and any statements of assumptions underlying any of the foregoing, including those relating to expected or future financial performance. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks and uncertainties related to global economic conditions, as well as the factors set forth in the Company’s Annual Report on Form 10-K for the year ended December 27, 2024 under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investor Information” section of the Company’s website under the heading “SEC Filings.” We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: global economic conditions; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before or after approval, or to take enforcement action; international trade disputes and substantial dependence on demand from Asia; and the willingness of surgeons and patients to adopt a new or improved product and procedure.

We intend to use our website as a means of disclosing material non-public information about the Company and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the ‘Investor Relations’ sections at investors.staar.com. Accordingly, investors should monitor such portion of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the News & Alerts section at https://investors.staar.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223189943/en/

Investor/Media Contact: ir@staar.com

Connie Johnson

cjohnson@staar.com

(626) 303-7902 (ext. 2207)

Asia Investor/Media Contact:

Niko Liu, CFA

nliu@staar.com

United States: (626) 303-7902 (ext. 3023)

Hong Kong: +852 6092-5076

Source: STAAR Surgical Company